Breast density remains a formidable obstacle in mammographic screening. Dense tissue masks tumors on X-rays by appearing similarly white, complicating the identification of cancerous lesions. DBT, which captures multiple X-ray images from various angles creating detailed breast images in three dimensions, has already improved detection accuracy compared to 2D mammography. Yet, its efficacy is attenuated in dense breasts, leaving a diagnostic gap. Here, Molecular Breast Imaging, employing radiotracers that highlight metabolic activity within breast tissue, offers a crucial functional perspective. By detecting areas of abnormal cellular activity, MBI can reveal cancers that evade structural imaging, bridging the limitations of DBT.

The Density MATTERS trial represents the first large-scale, multicenter prospective investigation assessing the complementary value of MBI alongside DBT in dense-breasted women. Conducted over five years across five diverse medical centers—including renowned institutions such as the Mayo Clinic, MD Anderson Cancer Center, and Henry Ford Health System—it enrolled nearly 3,000 asymptomatic women aged 40 to 75 with visually confirmed dense breasts. Participants underwent two rounds of annual simultaneous DBT and MBI screening, with comprehensive one-year clinical follow-ups enhancing data fidelity. This rigorous design allowed thorough appraisal of the incremental diagnostic yield afforded by MBI beyond standard tomosynthesis.

The outcomes were striking. Across both screening rounds, MBI exclusively detected 30 breast cancer lesions in 29 participants that were not identified by DBT. Crucially, 71% of these MBI-only detected cancers were invasive, with a median tumor size of just 0.9 centimeters—indicative of early-stage malignancies. Further pathology revealed that the majority (90%) were node-negative, suggesting a higher likelihood of curative intervention and improved prognoses. Meanwhile, 20% of these lesions harbored nodal involvement, emphasizing that MBI unmasks not merely indolent tumors but biologically significant disease that would otherwise remain occult on conventional imaging.

The study reported that MBI contributed an additional 6.7 invasive cancers per 1,000 screenings in the first year and 3.5 additional invasive cancers per 1,000 in the second year beyond those found by DBT alone. Notably, in detecting node-positive disease—a critical marker of advanced cancer—DBT alone identified only 57% of cases in year one, whereas combined imaging detected all. Although in the second year, some node-positive cancers remained undetected by either modality, the synergistic benefit of combining MBI with DBT led to a substantial jump in identification rates, potentially forestalling progression to more advanced disease stages.

These data suggest that MBI, leveraging a radiotracer with a long-standing safety profile from cardiac imaging, represents a low-risk yet highly efficacious supplemental screening tool. Unlike contrast-enhanced mammography or MRI, MBI involves fewer patient inconveniences and adverse reactions. Moreover, it operates at a relatively moderate cost compared to alternative modalities, rendering it a practical choice for widespread supplemental screening. This positions MBI as a compelling adjunct in personalized breast cancer screening strategies for women with dense breasts, a population historically underserved by conventional mammographic modalities.

Lead investigator Dr. Carrie B. Hruska from the Mayo Clinic emphasized the importance of these findings for both clinical practice and public health. “Women deserve screening protocols that maximize early cancer detection while minimizing unnecessary procedures,” she stated. “Our trial confirms that MBI as a supplement to DBT can identify cancers that would have otherwise gone unnoticed, many of which are aggressive invasive cancers with significant clinical implications.” She highlighted the trial’s incorporation of diverse clinical settings, including academic centers and community hospitals, enhancing the generalizability and real-world applicability of the results.

An important aspect of the Density MATTERS study was its attention to demographic representation. With 12% minority enrollment, the research addresses prior concerns about the applicability of imaging studies predominantly conducted in less diverse populations. As breast cancer incidence and outcomes vary across racial and ethnic groups, ensuring broad population inclusion is essential for equitable healthcare advancements. This inclusivity bolsters confidence that the combined screening strategy can be beneficial across multiple demographic segments.

While the study advocates for greater awareness about the detection limitations of DBT, it does not downplay the vital role of mammography. Instead, it encourages informed patient-clinician discussions to evaluate supplemental options tailored to individual risk profiles and breast density. MBI, with its demonstrated safety and tolerability, offers women and providers a viable pathway to enhance cancer detection, potentially reducing the incidence of diagnosis at advanced stages that carry poorer outcomes.

Looking forward, ongoing research efforts will likely focus on optimizing screening intervals, integrating MBI with other imaging modalities, and refining imaging protocols to balance sensitivity with specificity. Real-world implementation studies could evaluate cost-effectiveness, patient acceptance, and the long-term impact on breast cancer mortality. The Density MATTERS trial represents a pivotal step in evolving breast cancer screening paradigms toward more nuanced, individualized approaches that address challenges posed by breast density.

In conclusion, the pairing of Molecular Breast Imaging with Digital Breast Tomosynthesis marks a significant leap in breast cancer diagnostics for women with dense breasts. This innovative combination enhances the detection of invasive and clinically important cancers beyond what DBT alone can achieve, offering hope for earlier interventions and improved patient outcomes. The implications of this study resonate widely within the radiology and oncology communities, heralding a new era of precision screening and potentially shifting standards of care in breast imaging.

Subject of Research: People

Article Title: Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial

News Publication Date: 23-Sep-2025

Web References:

• Radiology journal: https://pubs.rsna.org/journal/radiology
• Radiological Society of North America (RSNA): https://www.rsna.org/
• Patient information on breast imaging: http://www.radiologyinfo.org

Image Credits: Radiological Society of North America (RSNA)

Keywords: Breast cancer, Mammography, Molecular imaging

The crux of this hybrid strategy lies in the integration of AI’s probability of malignancy (PoM) outputs with a quantifiable measure of uncertainty. Traditional AI systems, despite exhibiting impressive diagnostic capabilities, often struggle with overconfidence in their predictions, which can undermine their clinical reliability. Addressing this challenge, the Dutch team incorporated an uncertainty metric based on entropy calculations of the AI’s predicted malignancy probabilities for regions deemed suspicious on mammograms. This dual-output mechanism ensures that AI flags only those cases for autonomous reading where prediction confidence is high, thus adding a vital layer of safety and interpretive nuance.

The dataset anchoring this research is notably comprehensive, encompassing 41,469 screening mammograms acquired from 15,522 women between 2003 and 2018 as part of the Dutch National Breast Cancer Screening Program. With a median patient age of 59 years, the collection includes 332 screen-detected cancers and 34 interval cancers. The data was stratified into two equal cohorts: one to calibrate the AI thresholds defining the hybrid model, and the other to rigorously evaluate its performance. This careful division allowed the researchers to optimize the balance between sensitivity and specificity, a delicate equilibrium essential in cancer screening.

Through methodical analysis, the team determined that the entropy of the mean PoM score in the most suspicious mammographic region was the most effective uncertainty metric. This measure produced detection and recall rates closely paralleling those achieved via the conventional double-reading approach, where two radiologists independently interpret each screen. In practice, the AI system evaluates mammograms, producing a malignancy probability alongside an uncertainty score. When the malignancy probability falls beneath a set level and the AI expresses high confidence, the case is categorized as normal, thereby obviating the need for human review. Conversely, predictions with high malignancy probabilities and low uncertainty trigger recalls for further investigation, while the indeterminate cases are forwarded to radiologists for double reading.

One of the most striking findings emerged from the distribution of AI decision confidence: despite the fact that most AI predictions were uncertain, roughly 38% of cases were deemed sufficiently confident to be read solely by the AI. This selective delegation of cases translated to a workload reduction for radiologists to 61.9% of current levels, all while maintaining consistent recall rates (23.6 per 1,000 cases compared to 23.9 per 1,000 cases) and cancer detection rates (6.6 per 1,000 cases compared to 6.7 per 1,000). Such results underscore the model’s potential to preserve clinical standards while streamlining the labor-intensive screening process.

Importantly, the model’s diagnostic accuracy improved markedly when AI made confident judgments. The area under the receiver operating characteristic curve (AUC) reached 0.96 in confident AI reads, a significant elevation from the 0.87 recorded when AI decisions were uncertain. Sensitivity figures nearly paralleled the established double-reading paradigm, with 85.4% sensitivity for the confident AI reads versus 88.9% from dual radiologist interpretations. These performance metrics suggest that AI, armed with uncertainty quantification, can not only share but occasionally rival human diagnostic acumen in breast cancer screening.

The study also illuminated demographic factors influencing AI uncertainty. Younger women and those with dense breast tissue were more frequently classified as uncertain by the AI, reflecting known challenges in mammographic interpretation related to breast density and age-related tissue characteristics. This variability in uncertainty underscores the necessity of hybrid models that incorporate human oversight for complex or ambiguous cases, thus preserving patient safety and diagnostic integrity.

Sarah D. Verboom, M.Sc., lead author and doctoral candidate at Radboud University Medical Center, emphasized that the hallmark of their approach is less about workload redistribution and more about incorporating AI uncertainty as a trust-enhancing parameter. She advocates for commercial AI platforms to integrate such uncertainty quantification, believing it to be a pivotal component for clinical acceptance and ethical deployment. This paradigm shift, where AI transparency complements diagnostic precision, could accelerate AI integration in clinical practice.

The implications of these findings extend beyond radiologist workload. By allowing AI to autonomously evaluate a substantial subset of women’s mammograms, potentially up to 19% in this model, the clinical workflow can be expedited without compromising quality. This could alleviate workforce shortages and reduce the tedious burden of routine case reading, freeing radiologists to focus on challenging cases and interventional procedures. Moreover, the hybrid system may bridge the gap between patient acceptance and technological advancement, as surveys indicate most women prefer at least one radiologist’s review in their screening process.

False positives—a perennial concern in cancer screening—were not worsened by the hybrid model. Recall rates remained stable, reinforcing the AI’s cautious approach when uncertain. In fact, the AI’s ability to flag uncertainty may prevent premature recalls and unnecessary biopsies, enhancing the overall patient experience. The combination of improved confidence calibration and human oversight offers a safeguard against the pitfalls of AI overreach.

Future directions highlighted by the research team include prospective trials to validate the hybrid strategy in real-world settings and to quantify actual reductions in reading time and cost savings. Additionally, there is interest in refining uncertainty metrics and integrating continuous quality control mechanisms to monitor AI performance post-deployment. Such efforts are critical for regulatory approval and clinical adoption, ensuring that AI tools complement, rather than complicate, radiological workflows.

This study is a component of the broader aiREAD project, supported by prestigious bodies including the Dutch Research Council, the Dutch Cancer Society, and Health Holland. Its multidisciplinary approach marries cutting-edge computer science with clinical medicine, epitomizing the collaborative spirit essential for medical AI innovation. As AI continues to evolve, strategies that balance autonomy with clinician engagement are likely to define its successful application in cancer screening.

In conclusion, this hybrid AI-human reading strategy represents a sophisticated advancement that leverages AI’s computational strengths while respecting the complexity and nuance inherent in breast cancer diagnosis. By explicitly accounting for AI uncertainty, it paves the way for more reliable, efficient, and patient-centered screening programs. As technology continues to mature, such thoughtful integration of AI promises to revolutionize disease detection and management, ultimately improving outcomes and optimizing healthcare resources.

Subject of Research: People
Article Title: AI Should Read Mammograms Only When Confident: A Hybrid Breast Cancer Screening Reading Strategy
News Publication Date: 19-Aug-2025
Web References: https://pubs.rsna.org/journal/radiology, https://www.rsna.org/
Image Credits: Radiological Society of North America (RSNA)
Keywords: Artificial intelligence, Mammography, Breast cancer